Palatin Technologies, Inc., was incorporated under the laws of the State of Delaware on November 21, 1986. The company is a professional biopharmaceutical company developing first-in-class drugs based on molecules that regulate the activity of the melanocortin and natriuretic peptide receptor systems. The company's product candidates are targeted, receptor-specific treatments for diseases with significant unmet medical needs and commercial potential. 

Palatin Technologies shares jump 10.93% after-hours on focus on peptide therapies and potential biotech breakthroughs.

PTN News